QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
A recent international study examined the ability of an artificial intelligence (AI) system to detect clinically significant prostate cancer on MRI scans, comparing it to that of experienced radiologists using the Prostate Imaging- Reporting and Data System version 2.1 (PI-RADS…
• Newsweek/Showmark, “Your America’s Best Prostate Cancer Surgeons 2025.” • Chicago Magazine, “Top Doctors in America Recognized for Excellence 2025” • Nominated for Who’s Who in America 2025 • ScholarGPS celebrates highly ranked scholars for their exceptional performance in various…
Thirty years ago, at age 64, through PSA testing, Eugene (Gene) Golub received a diagnosis of prostate cancer. He consulted Dr. Catalona, who then worked at Washington University in St. Louis and successfully treated him. Years later, they reconnected at…
Multiparametric Magnetic Resonance Imaging (mpMRI) improves the pathway for diagnosing prostate cancer and detecting the clinically significant form of this disease. Moreover, some with a negative MRI scan can avoid prostate biopsy. In routine clinical practice, the PI-RADS scoring system…
SEER Cancer, the authoritative source for cancer statistics in the US, estimates that about 7 out of 8 men will never be diagnosed with prostate cancer during their lifetime, and nearly 90% who receive the diagnosis never suffer or die…
The goal of PSA screening is to test asymptomatic men and improve health outcomes by diagnosing the cancer at an early stage. A benefit of screening is to decrease the proportion of advanced-stage cases at the time of diagnosis and…
Researchers develop artificial intelligence (AI) algorithms via machine learning analysis of scanned biopsy slide images. They can identify patterns associated with prostate cancer in its various microscopic patterns. These algorithms are trained progressively based on classifying cases and controls regarding…
Dr. Catalona and his collaborators studied the associations between the patient’s germline genomic polygenic risk score (PRS) and prostate cancer tumor upgrading and tumor features in men enrolled in an active surveillance program.1 They used the new PRS consisting of…
There has been a long debate about whether drinking alcohol increases the risk of prostate cancer (PCa). Some studies show that drinking, especially in large amounts, is linked to higher chances of developing PCa, while others have suggested that wine…
The TheraP study compared two treatments, (1) lutetium-177 [177Lu]Lu-PSMA-617 and (2) a chemotherapy agent, cabazitaxel, for men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy with docetaxel. This phase 2 trial, conducted at 11 centers in Australia, focused…
"*" indicates required fields
